BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 23030360)

  • 21. Antibody-mediated suppression of grafted lymphoma. III. Evaluation of the role of thymic function, non-thymus-derived lymphocytes, macrophages, platelets, and polymorphonuclear leukocytes in syngeneic and allogeneic hosts.
    Shin HS; Hayden M; Langley S; Kaliss N; Smith MR
    J Immunol; 1975 Apr; 114(4):1255-63. PubMed ID: 1078832
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of aging on cellular immunity against cancer in SR/CR mice.
    Cui Z; Willingham MC
    Cancer Immunol Immunother; 2004 Jun; 53(6):473-8. PubMed ID: 14730401
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Two cytotoxic cells in peritoneal cavity of virus-infected mice: antibody-dependent macrophages and nonspecific killer cells.
    Macfarlan RI; Burns WH; White DO
    J Immunol; 1977 Nov; 119(5):1569-74. PubMed ID: 915270
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A protective role for interleukin 18 in interferon γ-mediated innate immunity to Cryptosporidium parvum that is independent of natural killer cells.
    Choudhry N; Petry F; van Rooijen N; McDonald V
    J Infect Dis; 2012 Jul; 206(1):117-24. PubMed ID: 22517912
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IL-12 is essential for resistance against Yersinia enterocolitica by triggering IFN-gamma production in NK cells and CD4+ T cells.
    Bohn E; Autenrieth IB
    J Immunol; 1996 Feb; 156(4):1458-68. PubMed ID: 8568248
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccination with B16 melanoma cells expressing a secreted form of interleukin-1beta induces tumor growth inhibition and an enhanced immunity against the wild-type B16 tumor.
    Björkdahl O; Dohlsten M; Sjögren HO
    Cancer Gene Ther; 2000 Oct; 7(10):1365-74. PubMed ID: 11059695
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanisms of in vivo generation of cytotoxic effector cells against tumor in tumor-bearing mice.
    Fuyama S; Yamamoto H; Fujii Y; Arai S
    Cancer Res; 1986 Nov; 46(11):5548-52. PubMed ID: 2428480
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effector cells of low-dose IL-2 immunotherapy in tumor bearing mice: tumor cell killing by CD8+ cytotoxic T lymphocytes and macrophages.
    Maas RA; Roest PA; Becker MJ; Weimar IS; Dullens HF; Den Otter W
    Immunobiology; 1992 Nov; 186(3-4):214-29. PubMed ID: 1490728
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suppression of in vitro maintenance and interferon-mediated augmentation of natural killer cell activity by adherent peritoneal cells from normal mice.
    Brunda MJ; Taramelli D; Holden HT; Varesio L
    J Immunol; 1983 Apr; 130(4):1974-9. PubMed ID: 6187831
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 5-halo-6-phenyl pyrimidinones: new molecules with cancer therapeutic potential and interferon-inducing capacity are strong inducers of murine natural killer cells.
    Lotzová E; Savary CA; Stringfellow DA
    J Immunol; 1983 Feb; 130(2):965-9. PubMed ID: 6848603
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
    Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cancer resistance of SR/CR mice in the genetic knockout backgrounds of leukocyte effector mechanisms: determinations for functional requirements.
    Sanders AM; Stehle JR; Blanks MJ; Riedlinger G; Kim-Shapiro JW; Monjazeb AM; Adams JM; Willingham MC; Cui Z
    BMC Cancer; 2010 Mar; 10():121. PubMed ID: 20356394
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hybrid resistance to BALB/c plasmacytomas: F1 hybrid anti-MPC-11 immunological responses correlated with resistance to tumor challenge.
    Marsili MA; Walker MC; Phillips-Quagliata JM
    Cancer Res; 1986 Jan; 46(1):190-7. PubMed ID: 3484380
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Attempts to correlate interferon induction and activation of natural killer cells by Corynebacterium parvum.
    Chmielarczyk W; Kirchner H; Ernst R; Storch E
    Immunobiology; 1985 May; 169(4):403-11. PubMed ID: 2408996
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Natural killer activity in the peritoneal exudates of mice infected with Listeria monocytogenes: characterization of the natural killer cells by using a monoclonal rat anti-murine macrophage antibody (M1/70).
    Holmberg LA; Springer TA; Ault KA
    J Immunol; 1981 Nov; 127(5):1792-9. PubMed ID: 6795262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations.
    van Ojik HH; Bevaart L; Dahle CE; Bakker A; Jansen MJ; van Vugt MJ; van de Winkel JG; Weiner GJ
    Cancer Res; 2003 Sep; 63(17):5595-600. PubMed ID: 14500400
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of NK cell magnetic bead isolation methods on phenotype and function of murine NK cells.
    Meinhardt K; Kroeger I; Abendroth A; Müller S; Mackensen A; Ullrich E
    J Immunol Methods; 2012 Apr; 378(1-2):1-10. PubMed ID: 22306357
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Whole tumor cell vaccine with irradiated S180 cells as adjuvant.
    Li J; King AV; Stickel SL; Burgin KE; Zhang X; Wagner TE; Wei Y
    Vaccine; 2009 Jan; 27(4):558-64. PubMed ID: 19027812
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor cell-triggered macrophage-mediated suppression of the T-cell cytotoxic response to tumor-associated antigens. I. Characterization of the cell components for induction of suppression.
    Ting CC; Rodrigues D
    J Natl Cancer Inst; 1982 Oct; 69(4):867-72. PubMed ID: 6214653
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NK cell depletion results in accelerated tumor growth and attenuates the antitumor effect of total body irradiation.
    Miller GM; Andres ML; Gridley DS
    Int J Oncol; 2003 Dec; 23(6):1585-92. PubMed ID: 14612930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.